ClinicalTrials.gg
CompletedNCT04567667Updated Jun 2, 2022

Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants

A Phase 1 interventional study of [14C] BMS-986278 and Kinevac® in Healthy Volunteers, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to male participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-02.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Apr 2021, 5 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Non-randomized
Ages
21 Years to 65 Years
Sex
Male
01

Study summary

The purpose of this study is to assess the way the body absorbs, distributes, breaks down and eliminates radioactive BMS-986278 as well as the safety and tolerability of BMS-986278 in healthy male participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy volunteers
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • No deviation from normal in medical history, physical examination, (ECGs), vital signs, and clinical laboratory determinations
  • (BMI) of 18.0 to 30.0 kg/m2, inclusive, and total body weight ≥50 kg (110 lb), at screening. BMI = weight (kg)/(height [m])2
  • Males must agree to follow specific methods of , if applicable

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical condition that presents a potential risk to the participant and/or that may compromise the objectives of the study, including active, or history of, liver disease, or intestinal disorder including irritable bowel syndrome
  • Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could impact upon the absorption of study treatment
  • Any major surgery within 6 weeks of study treatment administration

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Group 1

    Drug: [14C] BMS-986278

  • Experimental
    Group 2

    Drug: [14C] BMS-986278 · Drug: Kinevac®

Interventions

  • Specified dose on specified days

  • DrugKinevac®

    Specified dose on specified days

    Also known as: Sincalide

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of BMS-986278

    Time frame: Up to 15 days

  2. Maximum observed plasma concentration (Cmax) of total radioactivity (TRA)

    Time frame: Up to 15 days

  3. Time of maximum observed plasma concentration (Tmax) of BMS-986278

    Time frame: Up to 15 days

  4. Time of maximum observed plasma concentration (Tmax) of TRA

    Time frame: Up to 15 days

  5. Area under the plasma concentration-time curve extrapolated to infinity (AUC(INF)) of BMS-986278

    Time frame: Up to 15 days

  6. Area under the plasma concentration-time curve extrapolated to infinity (AUC(INF)) of TRA

    Time frame: Up to 15 days

Secondary outcomes

  1. Incidence of Adverse Events (AEs)

    Time frame: Up to 15 days

  2. Incidence of Serious Adverse Events (AEs)

    Time frame: Up to 73 days

  3. Incidence of clinically significant changes in clinical laboratory results: Hematology tests

    Time frame: Up to 43 days

  4. Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests

    Time frame: Up to 43 days

  5. Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests

    Time frame: Up to 43 days

  6. Incidence of clinically significant changes in vital signs: Blood pressure

    Time frame: Up to 43 days

  7. Incidence of clinically significant changes in vital signs: Heart rate

    Time frame: Up to 43 days

  8. Incidence of clinically significant changes in vital signs: Respiratory rate

    Time frame: Up to 43 days

  9. Incidence of clinically significant changes in vital signs: Body temperature

    Time frame: Up to 43 days

  10. Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF

    QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave.

    Time frame: Up to 43 days

  11. Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval

    The QT interval is the time from the start of the Q wave to the end of the T wave.

    Time frame: Up to 43 days

  12. Incidence of clinically significant changes in physical examination findings

    Time frame: Up to 43 days

07

Study locations

1 site
  • Covance - Clinical Pharmacology Services - Madison
    Madison, Wisconsin 53704, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2020 to primary completion in Apr 2021, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2020
First posted
Sep 28, 2020
StartActual
Oct 15, 2020
Primary completionActual
Apr 11, 2021
CompletionActual
Apr 11, 2021
Last update
Jun 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04567667
Responsible party
Sponsor
First posted
Sep 28, 2020
Start date
Oct 15, 2020
Primary completion
Apr 11, 2021
Completion
Apr 11, 2021
Last update
Jun 2, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Admilparant

Start the discussion